Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection

Transplantation

Volumn 68, Issue 9, 1999, Pages 1417-1420

  Rebello, Perpetua R U B ^b   Hale, Geoffrey ^a   Friend, Peter J ^b   Cobbold, Stephen P ^b   Waldmann, Herman ^b  

^a Therapeutic Antibody Centre   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY;

ARTICLE; CLINICAL ARTICLE; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0033571271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00032     Document Type: Article

References (15)

1. Norman DL, Chatenoud L, Cohen L, Goldman M, Shield CF. Consensus statement regarding OKT3-induced cytokine release syndrome and human anti-mouse antibodies. Transplant Proc 1993; 25: 89.
2. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42.
3. Hale G. Campath-1 Antigen (CD52). In: Delves PJ, Roitt I, eds. Encyclopedia of immunology London: Academic Press 1998; 402.
4. Friend PJ, Waldmann H, Hale G, et al. Reversal of allograft rejection using the monoclonal antibody CAMPATH-1G. Transplant Proc 1991; 23: 1390.
5. Hale G, Phillips JM. Clinical trials with CAMPATH-1 and other monoclonal antibodies. Biochem Soc Trans 1995; 23: 1057.
6. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323.
7. Friend PJ, Rebello P, Oliveira D, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc 1995; 27: 869.
8. Cobbold SP, Rebello PRUB, Davis Hff, Friend PJ, Clark MR. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990; 127: 19.
9. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Humanised monoclonal antibody treatment for intractable systemic vasculitis. Lancet 1993; 341: 1620.
10. Kimball JA, Norman DJ, Shield CF, et al. The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transplant Immunol 1995; 3: 212.
11. Klus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies? Clin Diag Lab Immunol 1994; 1: 365.
12. Isaacs JD. The antiglobulin response to therapeutic antibodies. Semin Immunol 1990; 2: 449.
13. Isaacs JD, Watts RA, Hazleman BL, et al. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748.
14. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthrits Rheum 1995; 38: 1589.
15. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995; 38: 1187.